Toxicity and efficacy of the cetuximab-folfox regimen in first-line of ras wild-type metastatic colorectal cancer

A 9-year retrospective observational study (January 2009-December 2017) conducted in a 450-bed hospital. The aim of the study was to assess the toxicity and efficacy of the cetuximab-FOLFOX regimen in first-line therapy of RAS wild type metastatic colorectal cancer in daily clinical practice. The outcomes suggested a similar efficacy to prior published studies and an acceptable safety profile, mainly based on mild-moderate toxicity